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Abstract
Myotonic Dystrophy type 1 (DM1) is a multisystemic disease caused by toxic RNA from a
DMPK gene carrying an expanded (CTG•CAG)n repeat. Promising strategies for treatment
of DM1 patients are currently being tested. These include antisense oligonucleotides and
drugs for elimination of expanded RNA or prevention of aberrant binding to RNP proteins. A
significant hurdle for preclinical development along these lines is efficient systemic delivery
of compounds across endothelial and target cell membranes. It has been reported that DM1
patients show elevated levels of markers of muscle damage or loss of sarcolemmal integrity
in their serum and that splicing of dystrophin, an essential protein for muscle membrane
structure, is abnormal. Therefore, we studied cell membrane integrity in DM1 mouse models
commonly used for preclinical testing. We found that membranes in skeletal muscle, heart
and brain were impermeable to Evans Blue Dye. Creatine kinase levels in serum were simi-
lar to those in wild type mice and expression of dystrophin protein was unaffected. Also in
patient muscle biopsies cell surface expression of dystrophin was normal and calcium-posi-
tive fibers, indicating elevated intracellular calcium levels, were only rarely seen. Combined,
our findings indicate that cells in DM1 tissues do not display compromised membrane integ-
rity. Hence, the cell membrane is a barrier that must be overcome in future work towards ef-
fective drug delivery in DM1 therapy.
Introduction
Myotonic Dystrophy type 1 (DM1) is the most common form of muscular dystrophy in adults.
Patients with this disease carry an unstable (CTG)n repeat in the 3’UTR of the DMPK gene,
the length of which correlates with disease severity [1,2]. DM1’s molecular pathogenesis is
complex. Firstly, mutant DMPK RNAs with a long (CUG)n repeat are retained in the cell nu-
cleus, where they abnormally bind transcription and splicing factors, resulting in aberrant pro-
tein production and different downstream cellular effects [3]. Secondly, antisense transcripts
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from the mutant DM1 locus, which carry an expanded (CAG)n repeat, may contribute to the
imbalance in proteostasis in DM1 by the production of homopolymeric proteins via a process
called RAN translation [4]. Combined, these effects of (CTG•CAG)n expansion are thought to
compromise functional development and cause wasting of skeletal muscle (myotonia and mus-
cle weakness), heart (arrhythmia) and brain (mental retardation).
No cure for DM1 is available yet, but strategies for molecular therapy based on antisense
RNA, siRNA or oligonucleotides (AONs) [5,6,7,8,9,10,11], compounds that inhibit aberrant
(CUG)n RNA-protein interactions [12,13,14] or site-specific RNA endonucleases that target
(CUG)n repeats [15] are currently under development. As essentially all these strategies require
intracellular delivery of the therapeutic agents (oligonucleotides, high molecular weight organic
compounds or proteins), sophisticated approaches may be needed to promote uptake across bi-
ological membranes and reach effective tissue concentrations [e.g. 16].
Typically, efficacy of drug uptake into cells is dominantly controlled by molecular character-
istics of the cargo itself and by properties of the membranes. Functional changes in cell mem-
branes are central in the pathogenesis of many diseases [17]. For example, membrane
permeability can be altered by aberrant protein-membrane interactions, presence of aggrega-
tive proteins [18] or lack of integral membrane proteins, i.e. as seen with dystrophin in patients
with Duchenne muscular dystrophy (DMD) [19].
Despite its importance as parameter for efficacy of drug delivery, not much is known about
membrane integrity in tissues of DM1 patients. Abnormal red blood cell membranes in DM1
patients were noticed in the past [20,21,22]. Pathological features in skeletal muscles include
internal nuclei, ring fibers, sarcoplasmic masses, type-I fiber predominance and atrophy, fibro-
sis and fatty infiltration, and a greatly increased number of intrafusal muscle fibers [23]. Poten-
tially related to the myopathy, DM1 patients may show mildly elevated levels of markers of
muscle damage in serum [24], with a possible impact of exercise regimen on these parameters
[25]. Finally, aberrant splicing of dystrophin in DM1 patients has been reported [26], with as
yet unknown effects on muscle membrane function. All data combined suggest that a certain
level of membrane leakiness cannot be excluded in the highly complex DM1 phenotype.
Here, we investigated the possible involvement of membrane permeability in the context of
AON-mediated treatment for DM1 using mouse models that replicate DM1 characteristics, i.e.
inHSALR mice [27] and in DM500 [28,29] and DMSXL mice [30], both descendants from the
DM300-328 line [31] (Table 1). Better understanding of cell membrane properties in these ani-
mal models will support preclinical development of effective therapeutic strategies in DM1 pa-
tients. We report on membrane integrity and related membrane characteristics in these
models, in comparison to findings in wild type (WT) mice and mdx mice, a DMDmouse
model with leaky muscle membranes [32,33]. For comparison, these parameters were also
studied in muscle biopsies from DM1 patients. Our study combining mouse and human sam-
ples demonstrates that cells in DM1 tissues most likely have a functional membrane. Future
therapeutic studies in DM1 mouse models may therefore benefit from advanced targeting strat-
egies for effective therapeutics for DM1.
Materials and Methods
Ethics Statement
Animal experiments were approved by the Animal Ethics Committee of Radboud University
(Permit Number: RU-DEC 2012–102).
Human control #1 quadriceps muscle tissue was obtained from the VU University Medical
Center (VUmc, Amsterdam, The Netherlands). The use of post-mortem material was ap-
proved by the VUmc research committee (project 2011–67), where relatives have given explicit
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prior written consent that tissue taken at autopsy can be used for research, after completion of
the diagnostic process and informed consents were approved by institutional review boards.
Human control #2 and #3 quadriceps muscle tissues were obtained from a commercial tissue
bank (Cambridge Bioscience, Cambridge, UK; www.bioscience.co.uk). The bank provides fro-
zen human tissue samples that have been collected from pre-consented post-mortem donors in
the UK.
Quadriceps muscle biopsies from the six DM1 patients were taken by B. van Engelen in a
regular diagnostic procedure, performed routinely in the neuromuscular clinic. Oral informed
consent was received from all patients, documented in the patients' charts, to perform the pro-
cedure and to use the muscle material for research purposes.
A quadriceps biopsy from a DMD patient was authorized by Dr. M. Tulinius (University of
Göteborg, Sweden), with written informed consent for use in research from the patient’s pa-
rents, with approval by the Local Ethics Committee in Göteborg.
All biopsies were anonymized before they were handed over for research.
Human material
All information regarding human muscle samples used in this paper is summarized in Table 2.
Mice
DM500, DMSXL, HSALR and WTmice (similar background as DM500/DMSXL strains, i.e.
>90% C57BL/6) were bred under SPF conditions in the Central Animal Laboratory in Nijme-
gen. Female homozygous and male hemizygous mdx mice were purchased from The Jackson
Laboratory (Bar Harbor, ME, USA). For the DM500, DMSXL andHSALR lines homozygous
mice were used in experiments. From each mouse strain animals of different ages were used
(2–6 months for EBD experiments, average 3.5 months; 2–3 months for CK measurements, av-
erage 2.2 months) to avoid bias with regard to possible developmental changes. Male and fe-
male mice were used to exclude gender-specific effects.
Exercise regimen in treadmill
A five-lanes treadmill (Panlab/Harvard Apparatus, Holliston, MA, USA) with air-puff control
system and 0° slope inclination was used in the exercise regimen (adapted from [34]). Mice
Table 1. Mousemodels used in this study.
Mouse
model
Transgene/Mutation Promoter/Expression Phenotype/Symptoms Original
references
DM500 human DM1 locus with
~500 CTG triplets
human DMPK promoter/all DM1
related tissues (e.g., skeletal muscle,
heart, CNS)
homozygous mice: myopathy, reduced muscle
strength, myotonia (generally very mild phenotype)
[28,29]
DMSXL human DM1 locus with
~1600 CTG triplets
human DMPK promoter/all DM1
related tissues (e.g., skeletal muscle,
heart, CNS)
homozygous mice: myopathy, reduced muscle
strength, myotonia, reduced body size (more severe
phenotype than DM500 mice)
[30]
HSALR human α-actin gene with
~250 CTG triplets
human α-actin promoter/ skeletal
muscle only
homozygous mice: strong myotonia, myopathy, no
muscle weakness
[27]
mdx spontaneous point
mutation in dystrophin
gene
ubiquitous (e.g., skeletal muscle,
heart, CNS, retina)
hemizygous mice: muscle degeneration and atrophy,
skeletal muscle ﬁbrosis and necrosis
[32,33]
WT no transgene (genetic
background >90% C57BL/
6)
n.a. n.a. n.a.
doi:10.1371/journal.pone.0121556.t001
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were settled with the treadmill belt stationary for 2 minutes, followed by a warm-up period of
8 minutes at a speed of 8 m/minute, immediately followed by the main exercise regimen of
30 minutes at 12 m/minute. Five mice participated in each exercise session (one animal of each
strain). All mice performed well in the exercise regimen, except in one session, in which one
DMSXL mouse and one mdx mouse stopped running after 20 minutes. In that case the tread-
mill was stopped and a rest period of 2 minutes was given to all mice. After that, the exercise
was continued for 10 minutes without further difficulties.
Mouse blood collection and serum CK assay
Blood was collected before and after exercise via a tail cut (~100 μl/mouse). Samples were incu-
bated for 1 hour at room temperature to allow clotting and were then centrifuged at 12,000g
for 10 minutes at 4°C. Serum was collected and snap frozen in liquid nitrogen before storage at
-80°C. Serum samples were diluted 1:10 in 0.9% NaCl prior to analysis. CK activity was deter-
mined using the ARCHITECT system (Abbott Laboratories, Abbott Park, IL, USA) based on
the IFCC method for the measurement of catalytic activity of CK [35] at the Department of
Laboratory Medicine, Radboudumc.
EBD injection and tissue isolation
Evans Blue Dye (Sigma-Aldrich, St. Louis, MO, USA), 10 μg/μl in physiological saline (0.15 M
NaCl, 10 mM phosphate buffer, pH 7.4), sterilized by passage through a 0.2 μm pore size
membrane filter was injected intravenously through the tail vein 30 minutes after exercise
(50 μl/10 g body weight). Mice were sacrificed by cervical dislocation 24 hours later. Tissues
were immediately harvested and frozen in isopentane pre-chilled in liquid nitrogen.
Table 2. Summary of information on patients and human controls and results from this study.
Sample Gender DM1
phenotype
Estimated
(CTG)n length
in blood
CK value, in
U/L (age of
sampling)
Age at
muscle
biopsy, in
years
Estimated (CTG)n
length in muscle
biopsy (see S6
Fig.)
Dystrophin
expression in muscle
membrane, in a.u.
(mean ± CI)
Calcium-
positive ﬁbers
in muscle
biopsy
Control
#1
Male n.a. n.a. n.k. n.k. (adult) n.a. 146 ± 3 Absent
Control
#2
Male n.a. n.a. n.k. 62 n.a. 60 ± 2 Absent
Control
#3
Female n.a. n.a. n.k. 83 n.a. 94 ± 2 Rare
DM1 #1 Male Adult >200 670 (30), 1182
(32.6), 173
(32.9)
36 ~100–300 121 ± 5 Absent
DM1 #2 Male Adult n.k. 173 (n.k.) 48 ~100–200 103 ± 4 Absent
DM1 #3 Male Adult (mild) 41–100 735 (n.k.),
1198 (n.k.)
62 ~80–400 86 ± 6 Rare
DM1 #4 Male Adult >200 n.k. 48 ~100–400 146 ± 11 Rare
DM1 #5 Female Juvenile n.k. 123 (46) 41 ~100–500 n.d. Absent
DM1 #6 Male Adult n.k. n.k. 48 ~80–500 n.d. Absent
DMD Male n.a. n.a. n.k. 5 n.a. 7 ± 0.3 Abundant
n.a.: not applicable; n.k.: not known; n.d.: not determined
doi:10.1371/journal.pone.0121556.t002
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Tissue cryosectioning
10 μm tissue sections were prepared from a representative middle part of each of the six tissues
examined according to standard procedures using a Microm HM 500 Cryostat (Adamas
Instrumenten B.V., Rhenen, The Netherlands), dried and stored at -80°C until further use.
EBD quantification
For EBD imaging, sections were dried at room temperature, dipped in acetone, xylene and
mounted in DPX mounting solution (Fisher Scientific, Loughborough, UK). Images were ac-
quired by red autofluorescence in a Leica DMI6000B automated high-content microscope
(Leica Microsystems, Wetzlar, Germany) using the TRITC filter. The percentage EBD-positive
area was calculated by dividing the EBD-positive area by the total area of the section using
ImageJ software.
Immunohistochemistry
Mouse muscle cryosections were dried at room temperature and incubated for 1 hour in PBS
with 0.05% Tween-20 and 5% horse serum, followed by three washing steps in PBS for 5 min-
utes. Rabbit anti-dystrophin antibody ab15277 (Abcam, Cambridge, UK) was diluted in PBS
with 0.05% Tween-20 and 5% fetal bovine serum, applied to the sections and incubated for
2 hours. After washing in PBS 3 times for 5 minutes, sections were incubated with Alexa
488-conjugated goat anti-rabbit in PBS with 0.05% Tween-20 for 1 hour. Samples were rinsed
in PBS and then mounted in Mowiol containing 2.5% sodium azide overnight at room temper-
ature. Images were acquired by epifluorescence using the Leica microscope.
Immunostaining and quantification of dystrophin in human samples was done as described
[36]. In short, muscle cryosections were dried at room temperature and fixed in acetone for
1 minute, rinsed and washed with PBS for 5 minutes and blocked for 1 hour in PBS with 0.05%
Tween-20 and 5% horse serum, followed by another rinsing and washing step in PBS. Rabbit
anti-dystrophin ab15277 or IgG isotype antibody (used as control) were diluted in PBS with
0.05% Tween-20 and 5% fetal bovine serum and applied to the sections for 2 hours, followed
by 1 hour incubation with ab15277 and mouse anti-spectrin (Novocastra, Newcastle, UK)
combined. After rinsing and washing in PBS twice for 5 minutes, sections were incubated with
Alexa 488-conjugated goat anti-rabbit and Alexa 594-conjugated goat anti-mouse in PBS with
0.05% Tween-20 for 1 hour. Samples were rinsed and washed twice for 5 minutes in PBS and
then mounted using Vectashield (Vector Labs, Burlingame, CA, USA). Images were acquired
using the Zeiss LSM 710 confocal microscope (Zeiss, Oberkochen, Germany). The healthy con-
trol muscle section displaying the highest dystrophin intensity was used to adjust the confocal
settings for the Alexa 488 and 594 channel. These parameters were maintained for all other sec-
tions. To minimize variations in laser intensity due to changes in lamp temperature, the laser
intensity was kept constant by performing a calibration using a mirror slide. Four to five im-
ages per patient or control were acquired, which were subsequently processed using Definiens
Architect software (Definiens, Munich, Germany). The software used spectrin signal to locate
the membrane of muscle fibers and to define the region of interest. The operator manually ex-
cluded areas that were not correctly identified by the program. Dystrophin intensity was calcu-
lated in the region of interest, giving a representation of DMD expression per muscle fiber.
Calcium staining
Muscle sections were dried at room temperature and stained for 5 minutes in 1% Alizarin Red
S (Sigma-Aldrich, St. Louis, MO, USA) in distilled water adjusted to pH 5.4 with ammonium
Cell Membrane Integrity in DM1
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hydroxide, as recommended [37]. Samples were dehydrated in acetone (20 dips), incubated in
acetone-xylene (1:1) solution (20 dips) and cleared in xylene prior to mounting in DPX mount-
ing solution (Fisher Scientific, Loughborough, UK). Muscle slides were left to dry overnight at
room temperature and then stored at 4°C. Images were acquired in the Leica microscope with
a TX2 cube and a DFC480 color camera (Leica Microsystems, Wetzlar, Germany).
(CTG)n length determination by heat pulse extension PCR
Genomic DNA was isolated from muscle sections following standard procedures. To amplify
expanded (CTG)n repeats a heat pulse extension PCR protocol was used [38], that allows the
generation of DMPK (CTG)n amplicons of up to 1750 CTG repeats. 40 ng DNA was used in a
PCR mixture containing 2.25 M betaine (Fluka, Sigma-Aldrich, Germany), 0.2 mM dNTPs
(Invitrogen, Carlsbad, CA, USA), 1.33 units DyNAzyme EXT DNA Polymerase (Thermo Sci-
entific, Waltham, MA, USA) and 250 nM of each forward (5´-GCCAGTTCACAACCGCTCC
GAGCGTGGGTC-3´) and reverse (5´-ACGCTCCCCAGAGCAGGGCGTCATGC-3´) prim-
ers (Biolegio BV, Nijmegen, the Netherlands). Cycling conditions were kept as described [38],
except that an annealing temperature of 66°C followed by ramping to 83°C (0.9°C/sec) was
used. PCR was performed in a DNA engine Peltier Thermal Cycler (Bio-Rad, Hercules, CA,
USA). The size of the expected DMPK amplicon was 324 bp long excluding the (CTG)n repeat.
PCR products were run on a 1% agarose gel and transferred to a Hybond-XL nylon mem-
brane (Amersham, GE Healthcare). The blot was incubated with a 32P-end-labeled (CAG)9
probe and after washing exposed to a phosphor imager screen (Kodak, Rochester, NY, USA)
for 3 hours. Signal was developed using a Personal FX Phosphor Imager (Bio-Rad).
Statistics
To compare values of serum CK and EBD-positive fibers between groups, we used a one-way
ANOVA test. We applied a paired Student’s t-test to assess whether serum CK activity was sig-
nificantly different before and after the exercise regimen. All values in graphs are presented as
mean ± s.e.m. (unless indicated otherwise). Differences between groups were considered signif-
icant when P<0.05: , P<0.05; , P<0.01; , P<0.001. Statistical analyses were performed
with GraphPad Prism 5 software (GraphPad Software, Inc., La Jolla, CA, USA).
Results
For our study of cell membrane integrity we compared WTmice with DM500, DMSXL and
HSALR mice, three transgenic models frequently used in preclinical DM1 studies [39]
(Table 1). For an overt DM1 muscle phenotype, all three models were bred to homozygosity.
Mdx mice, a well-established model for DMD, were included as positive control, as these dem-
onstrate increased muscle fiber membrane permeability. To minimize possible effects of differ-
ences in physical activity between mice and to stimulate muscle contraction, mice were
subjected to a 30 minute exercise protocol on a motorized treadmill. Before and after exercise
several biomarkers for cell membrane integrity were measured.
Creatine kinase activity in mouse serum
Creatine kinase (CK) is released in the circulation upon muscle damage [40] or because of dis-
ease-induced loss of membrane integrity. Dystrophin-deficient mdx mice, for example, show
an increased basal serum CK level compared to control, which rises significantly after exercise
[34]. Under basal conditions, the three DM1 models showed similar serum CK values as WT
controls (Fig. 1A). In contrast, the corresponding levels in mdx mice were indeed around
Cell Membrane Integrity in DM1
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20-fold higher. After exercise, serum CK levels increased only around 2-fold in WT, DM500
and HSALR animals (Fig. 1B), whereas a 40-fold increase was observed in mdx mice. Markedly
enhanced sensitivity of DMSXL mice to exercise was detected, compared to the other DM1
models and WTmice (6-fold increase in CK level; Fig. 1). This effect was probably due to their
more severe muscle weakness phenotype, leading to extra muscle wasting necessary to com-
plete the exercise regime, rather than to intrinsic muscle membrane permeability of the model.
Nevertheless, neither basal CK levels nor levels after exercise in DMSXL mice were statistically
different from those in WT mice.
Evans Blue Dye uptake in mouse cells in vivo
To evaluate vasculature of living animals and integrity of cell membranes in vivo after exercise,
we used cell membrane-impermeable Evans Blue Dye (EBD) as tracer [41, 42]. EBD binds to
Fig 1. SerumCK level in DM1, mdx andWTmice. (A) CK levels were measured in mouse serum before
(blue) and after (red) exercise. CK level was significantly higher in mdx mice than in WT and DM1model
mice, both before and after the exercise regimen (P<0.001). Exercise resulted in a significant increase in CK
level in mdx mice (P<0.05), but not in other mice. (B) Exercise in the treadmill resulted in a forty-fold increase
in CK level in mdx mice, whereas only a two-fold increase was observed in WT, DM500 and HSALR mice and
a six-fold increase in DMSXLmice (n = 3–5 per genotype).
doi:10.1371/journal.pone.0121556.g001
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albumin in the bloodstream, leaks into muscle fibers that are damaged and can be observed mi-
croscopically by its red autofluorescence. DM1 mice did not show permeability to EBD in any
of the skeletal muscles investigated (quadriceps, gastrocnemius, tibialis anterior, diaphragm),
similar to WT controls (Fig. 2A,B; S1–S3 Figs.). As expected [41], relatively large, damaged
EBD-positive areas were present in mdx muscle. Only once, very few isolated positive fibers
were found in a quadriceps muscle of a DMSXL mouse (data not shown). We did not find posi-
tive fibers in heart in any of the mice examined (S4 Fig.), although it has been reported that
~50% of mdx mice show EBD-positive fibers in this tissue [41]. Finally, no EBD uptake was ob-
served in brain in any of the mice examined (S5 Fig.).
Dystrophin expression
Deficiency of dystrophin, a protein involved in muscle membrane structure and flexibility,
leads to progressive muscular dystrophy and degeneration in DMD patients and mdx mice
[32]. Also in DM1 patients, abnormal production of dystrophin isoforms has been demonstrat-
ed [26]. We verified dystrophin protein expression by immunohistochemistry in muscles of ex-
ercised DM1 animals and found that the staining pattern was indistinguishable from that in
WT mice in all tissues analyzed (Fig. 2C and S1–S4 Figs.). As expected, apart from few so-
called revertant fibers [43], no dystrophin staining was detected in mdx mice.
Cell membrane integrity in DM1 patients
To evaluate our findings obtained in DM1 mouse models, we investigated muscle membrane
integrity in human quadriceps muscle. We used biopsies from three healthy controls, six DM1
patients and one DMD patient. (CTG)n repeat lengths in the DM1 muscle biopsies ranged be-
tween ~80 and>500, as measured by heat pulse extension PCR [38] (S6 Fig.; Table 2). For
some of these patients slightly elevated CK levels had been measured in the past (Table 2).
As an alternative method to the EBD injections done in mice, we performed Alizarin Red
staining on human muscle sections to detect elevated intracellular calcium levels or deposits,
suggestive of membrane abnormalities [37]. Calcium-positive muscle fibers were indeed abun-
dant in DMDmuscle (Fig. 3A, Table 2). However, no or only few calcium-positive fibers were
observed in controls and DM1 patients.
Next, we performed immunostaining of dystrophin in serial muscle sections from the same
patients and controls. Spectrin immunostaining was used to visualize the membrane of muscle
fibers. In all healthy control and DM1 biopsies overt cell membrane expression of dystrophin
was observed, whereas essentially no dystrophin protein was detected in the DMD sample
(Fig. 3B). We quantified the amount of dystrophin using a novel method for immunofluores-
cence quantification [36]. Dystrophin expression in DM1 samples turned out to be similar to
that in control samples (Fig. 3C, Table 2). As expected, dystrophin level in the DMD sample
was extremely low.
Discussion
Efficient systemic cellular uptake of therapeutics is an important determinant for the success of
future clinical trials in DM1, because all known molecular targets, e.g., expanded (CUG)n/
(CAG)n transcripts or CELF1 and MBNL1 proteins that bind to these repeat-containing RNAs
[44] are located intracellularly. The effective concentration of any DM1 drug will therefore de-
pend on its chemical and pharmacokinetic characteristics and the ability to pass plasma mem-
branes of endothelial cells and target cells in muscle, heart or brain of patients. From research
on DMD, we have learned that the disease-related loss of dystrophin alters membranes of
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Fig 2. Membrane integrity analysis in mouse quadricepsmuscle. (A) Representative images of quadriceps sections from DM1mice and controls after
injection with EBD following exercise. OneWTmouse was not injected to appreciate autofluorescent background signal (No EBD). Areas with EBD-positive
fibers were regularly seen in mdx samples (arrowheads), but never in WT nor DM1model samples. Scale bars indicate 250 μm. (B) Quantification of the
EBD-positive area compared to total muscle section (n = 4 per group). (C) Representative images of quadriceps sections stained for dystrophin. Staining
Cell Membrane Integrity in DM1
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muscle and brain cells, leading to increased permeability for oligonucleotides and other large
molecules [19].
In this study, in comparison to the situation in DMD, we examined cell membrane integrity
in DM1 mouse models and in patient muscle biopsies. Our findings on human material suggest
that cell membranes in DM1 patients are intact. Expression and localization of dystrophin was
normal. We therefore assume that sufficient functionally active protein was present to support
membrane function, in spite of an abnormal dystrophin splice mode that affects the protein's
c-terminus responsible for interaction with the sarcolemma [26]. Furthermore, in concordance
with previous studies [37], calcium deposits, indicative of membrane damage, were rare or ab-
sent in DM1 muscle biopsies tested.
In a group of moderately affected, ambulatory DM1 patients one in four male patients and
one in two female patients showed mildly elevated basal CK values in serum [24]. Fluctuating,
slightly elevated CK levels were also measured in our small cohort of DM1 patients (Table 2).
These elevated CK values could be related to a mild membrane defect but, more likely, they are
related to myopathy and associated with tissue loss in these patients. More extensive clinical
studies in a much larger cohort of individuals are necessary to relate CK values in serum to
known variables of DM1 manifestation—e.g. (CTG•CAG)n-repeat length, somatic repeat ex-
pansion rate, disease onset and severity, and exercise and life-style habits—before we can draw
further conclusions.
The main focus of our study was to obtain better understanding of cell membrane integrity
in transgenic DM1 mouse models currently in use for testing new therapies [44]. From a series
of observations in models that faithfully replicate most important characteristics of disease in
DM1 [39], we conclude that cell membrane function is not affected by presence of repeat RNA.
Firstly, we found that serum CK levels in all three models are normal. Even after intense exer-
cise, only a two- to six-fold increase was measured, similar to wild type control animals. Sec-
ondly, dystrophin immune-staining was comparable to that in WT mice. Thirdly, we did not
observe permeability to EBD in any of the tissues analyzed. With respect to the HSALR model,
our microscopy findings match those presented in an earlier report, where EBD presence was
measured in whole muscle lysates by spectrophotometry, using a protocol without exercise reg-
imen [9].
It should be noted that we cannot exclude the possibility that cell membrane integrity in
DM1 mice might deteriorate during aging. This aspect was not part of our study and we chose
the age group of 2–6 month-old mice, since mice of that age are usually included in therapeutic
studies for DM1. For the DMSXL strain in particular, it has been shown that the strongest
symptoms are indeed seen in rather young mice [30].
Most of the treatments for DM1 that are currently under development involve the use of rel-
atively large compounds that neutralize expression of expanded DMPK transcripts or block
binding to MBNL1 [44, 45]. For these approaches to become effective, active compounds must
reach the cell nucleus, i.e., the cellular compartment where most of the toxic (CUG)n RNA is
located. Since we find no evidence for membrane alterations or increased membrane perme-
ability in the transgenic DM1 mice, we assume that drugs that were administered systemically
and showed efficacy in preclinical studies must have reached their destination via naturally ex-
isting cellular uptake and routing mechanisms either independently [9, Mulders et al. unpub-
lished, 12] or promoted by advanced targeting moieties [8, Mulders et al. unpublished]. Based
on our findings, we consider it unlikely that the disease state had a major effect on drug fate in
intensity and pattern observed in WT animals were very similar to those observed in DM500, DMSXL andHSALR mice. Right panels show high
magnifications of insets to appreciate dystrophin staining. As expected, essentially no signal was detected in mdx mice. Scale bars indicate 150 μm.
doi:10.1371/journal.pone.0121556.g002
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Fig 3. Membrane integrity analysis in DM1 patient biopsies. (A) Calcium staining using Alizarin Red S. No or only few calcium-positive fibers
(arrowheads), indicative of abnormal elevated calcium level, were found in DM1 and control biopsies. Calcium deposits were abundant in the DMD sample.
DMDmuscle sections showed fatty tissue infiltration (asterisks) and fibrosis (stars), which were also detected in some of the DM1 patient biopsies. Scale
bars indicate 100 μm. Results from only one of the three controls and three of the six examined DM1 patients are shown. All data are summarized in Table 2.
(B) Dystrophin immunostaining. In contrast to the DMD patient biopsy, expression and localization of dystrophin in DM1 and control quadriceps muscles were
normal. Spectrin staining was included as a cell membrane reference. Scale bars indicate 100 μm. (C) Quantification of dystrophin expression. Data is
represented as mean intensity per fiber (n>50). Error bars indicate 95% confidence interval (CI). Data are summarized in Table 2.
doi:10.1371/journal.pone.0121556.g003
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these studies, although we do not know whether carrier-mediated transport, receptor-mediated
endocytosis or any other transport route was involved [46, 47].
In sum, we conclude that cell membranes of DM500, DMSXL and HSALR mice are intact
and have normal physical stress resistance and properties for chemical passage. Our observa-
tions in muscle biopsies from DM1 patients corroborate this picture. Further study is now nec-
essary to know how compounds that have been shown to bind or degrade (CUG)n RNA are
internalized by myofibers or other cell types. Future therapeutic studies in DM1 mouse models
may benefit from advanced targeting strategies for effective therapeutics for DM1, given the
fact that cell membranes are probably intact in patients. As there is no need to concentrate
these studies on DM1-affected tissues only, this opens up prospects for the simultaneous devel-
opment of therapy for other neurodegenerative disorders.
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